144 related articles for article (PubMed ID: 11079284)
21. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine.
Mushet GR; Miller D; Clements B; Pait G; Gutterman DL
Headache; 1996 Mar; 36(3):137-43. PubMed ID: 8984084
[TBL] [Abstract][Full Text] [Related]
22. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine.
Tfelt-Hansen P; Henry P; Mulder LJ; Scheldewaert RG; Schoenen J; Chazot G
Lancet; 1995 Oct; 346(8980):923-6. PubMed ID: 7564725
[TBL] [Abstract][Full Text] [Related]
23. Cost savings in migraine associated with less chest pain on new triptan therapy.
Wang JT; Barr CE; Torigoe Y; Wang E; Rowland CR; Goldfarb SD
Am J Manag Care; 2002 Feb; 8(3 Suppl):S102-7. PubMed ID: 11859905
[TBL] [Abstract][Full Text] [Related]
24. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes.
Cohen JA; Beall D; Beck A; Rawlings J; Miller DW; Clements B; Pait DG; Batenhorst A
Clin Ther; 1999 Jan; 21(1):190-204. PubMed ID: 10090435
[TBL] [Abstract][Full Text] [Related]
25. Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone.
Cleland PG; Barnes D; Elrington GM; Loizou LA; Rawes GD
Eur Neurol; 1997; 38(1):31-8. PubMed ID: 9252796
[TBL] [Abstract][Full Text] [Related]
26. Migraine: which triptan?
Peatfield RC
Hosp Med; 1999 Apr; 60(4):277-80. PubMed ID: 10396434
[TBL] [Abstract][Full Text] [Related]
27. Switching patients with migraine from sumatriptan to other triptans increases primary care costs.
Savani N; Martin A; Browning D
Int J Clin Pract; 2004 Aug; 58(8):758-63. PubMed ID: 15372848
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of sumatriptan in a managed care population.
Legg RF; Sclar DA; Nemec NL; Tarnai J; Mackowiak JI
Am J Manag Care; 1997 Jan; 3(1):117-22. PubMed ID: 10169243
[TBL] [Abstract][Full Text] [Related]
29. Sumatriptan use in a large group-model health maintenance organization.
Greiner DL; Addy SN
Am J Health Syst Pharm; 1996 Mar; 53(6):633-8. PubMed ID: 8800968
[TBL] [Abstract][Full Text] [Related]
30. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective.
Lofland JH; Johnson NE; Batenhorst AS; Nash DB
Arch Intern Med; 1999 Apr; 159(8):857-63. PubMed ID: 10219932
[TBL] [Abstract][Full Text] [Related]
31. Sumatriptan. An updated review of its use in migraine.
Perry CM; Markham A
Drugs; 1998 Jun; 55(6):889-922. PubMed ID: 9617601
[TBL] [Abstract][Full Text] [Related]
32. Triptan therapy impacts health and productivity.
Weaver MB; Mackowiak JI; Solari PG
J Occup Environ Med; 2004 Aug; 46(8):812-7. PubMed ID: 15300133
[TBL] [Abstract][Full Text] [Related]
33. Different approaches to valuing the lost productivity of patients with migraine.
Lofland JH; Locklear JC; Frick KD
Pharmacoeconomics; 2001; 19(9):917-25. PubMed ID: 11700778
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study.
Sculpher M; Millson D; Meddis D; Poole L
Pharmacoeconomics; 2002; 20(2):91-100. PubMed ID: 11888361
[TBL] [Abstract][Full Text] [Related]
35. Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms.
Mannix LK; Adelman JU; Goldfarb SD; Von S; Kozma CM
Am J Manag Care; 2002 Feb; 8(3 Suppl):S94-101. PubMed ID: 11859910
[TBL] [Abstract][Full Text] [Related]
36. Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis.
Payne K; Kozma CM; Lawrence BJ
Pharmacoeconomics; 1996 Jul; 10(1):59-71. PubMed ID: 10160470
[TBL] [Abstract][Full Text] [Related]
37. Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses.
Salonen R; Saiers J
Cephalalgia; 1999 Jan; 19(1):16-9. PubMed ID: 10099854
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison.
Asseburg C; Peura P; Oksanen T; Turunen J; Purmonen T; Martikainen J
Int J Technol Assess Health Care; 2012 Oct; 28(4):382-9. PubMed ID: 23013610
[TBL] [Abstract][Full Text] [Related]
39. Economic implications of early treatment of migraine with sumatriptan tablets.
Cady RK; Sheftell F; Lipton RB; Kwong WJ; O'Quinn S
Clin Ther; 2001 Feb; 23(2):284-91. PubMed ID: 11293561
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the 'Act when Mild' study.
Slof J
Appl Health Econ Health Policy; 2012 May; 10(3):201-15. PubMed ID: 22320449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
